Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of fluconazole liquid in China. Welcome to wholesale bulk high quality fluconazole liquid for sale here from our factory. Good service and reasonable price are available.
Fluconazole liquid is a homogeneous liquid pharmaceutical formulation that takes fluconazole as its core therapeutic active ingredient. It is specially developed to elevate administration precision and boost long-term patient compliance during clinical antifungal treatment through optimized drug particle dispersion and enhanced long-term chemical stability within the solvent system. As a classic third-generation triazole-class antifungal agent, fluconazole delivers potent broad-spectrum antifungal effects. It selectively targets and suppresses 14 α-lanosterol demethylase belonging to the fungal cytochrome P450 enzyme complex, which interrupts the endogenous synthesis of ergosterol, an essential component of fungal cell membranes. This metabolic block drastically raises fungal cell membrane permeability and ultimately triggers fungal cell rupture and lysis. Notably, this medicine displays strong targeted inhibitory potency against common pathogenic fungi including Candida species, Cryptococcus species, and certain dimorphic biphasic fungi.
Additional information of chemical compound:
Our product forms
Fluconazole COA
Fluconazole liquid, as a broad-spectrum triazole antifungal drug, has become one of the preferred drugs for treating invasive fungal infections since its launch in 1988 due to its high efficacy, low toxicity, and good pharmacokinetic properties. Its mechanism of action involves multi-level molecular target interference and bioplast structure disruption.
This article will systematically elucidate the core mechanism of its antifungal effect from five dimensions: enzyme inhibition, inhibition of bioplast membrane synthesis, metabolic interference, bioplast structure disruption, and immune regulation.
Targeted fungal cytochrome P450 enzyme: a key step in inhibiting ergosterol synthesis
Enzyme specific binding and functional blockade
The core mechanism of action of Fluconazole is through its fluorinated triazole ring in its molecular structure, which specifically binds to the 14 α - lanosterol demethylase in the fungal cytochrome P450 enzyme family. This enzyme is a key rate limiting enzyme in the biosynthesis pathway of ergosterol, responsible for converting lanosterol into the precursor of ergosterol -14 demethylated lanosterol. The nitrogen atom of Fluconazole forms a coordination bond with the iron atom in the enzyme's active center, causing a conformational change in the enzyme and blocking oxygen activation and demethylation of lanosterol.
This process directly leads to the interruption of ergosterol synthesis, which is the main component of fungal bioplast membranes. Its absence can cause a significant increase in bioplast membrane permeability.Experimental evidence: In vitro studies have shown that Fluconazole has an inhibition constant (Ki) of 0.01-0.1 μ M for Candida albicans 14 α - demethylase, while its Ki value for human CYP3A4 is more than 100 times higher. This selective difference ensures that the drug has minimal metabolic impact on host bioplasts while inhibiting fungal growth.
Drug resistance mechanism and enzyme mutations
The resistance of fungi to Fluconazole mainly stems from mutations in the 14 α - demethylase gene (ERG11). For example, mutations such as Y132F and G464S in ERG11 of Candida albicans can cause changes in the spatial conformation of the enzyme active center, reducing the binding affinity of Fluconazole.In addition, some fungi (such as Candida krusei) exhibit inherent resistance to Fluconazole due to their natural lack of 14 α - demethylase or the existence of alternative sterol synthesis pathways.
The resistance mechanism of Candida auris involves the synergistic effect of ERG11 mutations and overexpression of efflux pumps (such as CDR1, MDR1).Clinical significance: The emergence of drug-resistant strains requires clinical doctors to adjust treatment plans based on drug sensitivity test results, such as switching to amphotericin B or 5-fluorocytosine for fluconazole resistant Cryptococcus infections.
Disrupting cell membrane integrity: from permeability changes to bioplast lysis
Chain reaction of ergosterol deficiency
The inhibition of ergosterol synthesis can cause cascade damage to fungal bioplast membranes:Reduced membrane fluidity: Ergosterol is a key component in maintaining bioplast membrane fluidity and stability, and its absence leads to increased membrane rigidity, affecting material transport and signal transduction.
Abnormal membrane protein function: Conformational changes in ergosterol dependent membrane proteins (such as transporters and enzymes) further interfere with nutrient uptake and metabolic waste excretion.
Leakage of bioplast contents: Increased membrane permeability leads to the loss of key molecules such as potassium ions and ATP within the bioplast, ultimately causing bioplast lysis.Experimental observation: Transmission electron microscopy showed significant wrinkling and rupture of the bioplast membrane of Candida albicans treated with Fluconazole, with cytoplasmic contents infiltrating into the extracellular matrix. Fluorescence staining experiments confirmed that the permeability of the bioplast membrane to propidium iodide (PI) significantly increased after drug treatment, indicating that membrane integrity was disrupted.
Clinical relevance
Bioplast membrane damage is the basis of Fluconazole's rapid bactericidal effect. In animal models, a decrease of over 90% in fungal colony forming units (CFU) can be observed within 2 hours after administration, which is directly related to changes in membrane permeability. In addition, pathogen associated molecular patterns (PAMPs) such as β - glucan exposed by membrane damage can activate the host immune system and enhance fungal clearance efficiency.
Interference with fungal metabolic network: Multi pathway inhibition of growth and reproduction
Comprehensive inhibition of sterol synthesis pathway
In addition to blocking ergosterol synthesis, Fluconazole also indirectly affects the accumulation of downstream sterol metabolites (such as yeast sterols and fecal sterols) by inhibiting 14 α - demethylase. These abnormal sterols will further interfere with the assembly and function of bioplast membranes, forming a "double blow" effect. For example, the accumulation of yeast sterols can alter the arrangement of membrane lipid bilayers, leading to abnormal embedding of membrane proteins.
HMG COA reductase
This enzyme is the rate limiting enzyme of the mevalonate pathway, and its inhibition reduces the supply of sterol synthesis precursors.Squalene cyclooxygenase: participates in the conversion of squalene to lanosterol, and its decreased activity exacerbates the obstruction of ergosterol synthesis.Metabolomics study: Through liquid chromatography-mass spectrometry (LC-MS) analysis, it was found that intermediate products such as lanosterol and 14 methyl lanosterol accumulated in Fluconazole treated Candida albicans bioplasts, while ergosterol and its derivatives levels significantly decreased. This metabolic characteristic is highly consistent with the mechanism of drug action.
Disrupting cell wall structure: synergistically enhancing antifungal effect
1. Interaction between cell wall and cell membrane
The fungal bioplast wall is composed of β - glucan, chitin, and mannan, and its synthesis depends on transport proteins on the bioplast membrane (such as Gwt1, Aus1). Fluconazole indirectly affects the function of these transporters by disrupting the bioplast membrane, leading to obstruction of the transport of bioplast wall synthesis materials such as UDP glucose. For example, the activity of Gwt1 enzyme depends on the presence of ergosterol on the bioplast membrane, and its impaired function can lead to exposure of bioplastwall β - glucan, increasing host immune recognition.
2. Activation of cell wall integrity signaling pathway
Bioplast wall damage triggers the fungal bioplast wall integrity (CWI) signaling pathway, which activates protein kinase C (PKC) and Mitogen activated protein kinase (MAPK) cascade reactions to induce the expression of bioplast wall repair related genes such as FKS1 and CHS3. However, under the sustained presence of Fluconazole, excessive activation of the CWI pathway can lead to increased intracellular oxidative stress, further exacerbating bioplast damage.
3.The synergistic effect of combination therapy
Preclinical studies have shown that the combination of Fluconazole and echinocandins (such as caspofungin) can produce synergistic antifungal effects.The former destroys the bioplast membrane, while the latter inhibits β - glucan synthesis, resulting in the collapse of the bioplast wall membrane complex and significantly improving bactericidal efficiency.
Immune regulatory effect: enhancing host defense capability
Regulating immune cell function
Fluconazole can enhance host immune response through the following mechanisms:Promote macrophage phagocytosis: After drug treatment, the exposure of fungal bioplast membrane components (such as β - glucan) increases, making them more easily recognized by macrophage pattern recognition receptors (such as Dectin-1), thereby enhancing phagocytic efficiency.Activation of complement system: Bioplast membrane damage leads to deposition of complement component C3b, promoting regulation of phagocytosis.
Regulating cytokine secretion: In vitro experiments, Fluconazole can induce human monocytes to secrete pro-inflammatory cytokines such as TNF - α and IL-1 β, while inhibiting the expression of anti-inflammatory factor IL-10, thereby enhancing immune clearance.
Clinical immunological evidence
In AIDS patients with cryptococcal meningitis, fluconazole liquid maintenance treatment can significantly reduce the recurrence rate, which is partly due to the regulation of host immune function by drugs.Research has shown that long-term medication patients have stable peripheral blood CD4+T bioplast counts and elevated levels of interferon - γ (IFN - γ) secretion.
Clinical application
Indications
Candidiasis
Oral and esophageal infections: The liquid formulation of fluconazole can effectively treat oral and esophageal candidiasis, alleviating symptoms such as oral ulcers and dysphagia.Sporadic candidiasis: Including peritonitis, pneumonia, urinary tract infections, etc., the liquid formulation of fluconazole can achieve systemic treatment through oral administration.Candida vulvovaginitis: For female patients, the liquid formulation of fluconazole can provide a convenient treatment method, reducing local medication discomfort.
Prevention of candidiasis: In bone marrow transplant patients receiving cytotoxic drugs or radiotherapy, the liquid formulation of fluconazole can be used to prevent the occurrence of candidiasis.
Cryptococcosis
New forms of cryptococcosis other than meningitis: The liquid formulation of fluconazole can be used to treat new forms of cryptococcosis, such as pulmonary and skin cryptococcosis.Maintenance treatment of cryptococcal meningitis: During the treatment of cryptococcal meningitis.
The liquid formulation of fluconazole can be used as a maintenance treatment drug after the initial treatment with amphotericin B and flucytosine, reducing the risk of recurrence.
Other fungal infections
Coccidioidomycosis: The liquid formulation of fluconazole can be used to treat coccidioidomycosis, alleviating patient symptoms.Histoplasmosis, histoplasminosis: The liquid formulation of fluconazole can be used as an alternative to itraconazole for the treatment of histoplasmosis and histoplasminosis.
Specific Population Applications
Children patients
Precise dosing: The liquid formulation of fluconazole can be precisely dosed according to the weight of children, avoiding excessive or insufficient medication, and improving treatment safety.High cure rate: Studies show that the liquid formulation of fluconazole for treating oral thrush in children with immunodeficiency has a cure rate of up to 91% and a fungal eradication rate of up to 76%, significantly better than nystatin.Good tolerance: For children or patients with esophageal symptoms.
Immunosuppressed population
Prevention of infection: The liquid formulation of fluconazole can be used to prevent fungal infections in bone marrow transplant recipients, cancer chemotherapy patients, HIV-infected individuals, etc., who have immunosuppression.Treatment of infection: For immunosuppressed individuals who have already developed fungal infections, the liquid formulation of fluconazole can provide effective treatment methods.
Elderly patients
Adjusting dosage for renal insufficiency: Elderly patients often have renal insufficiency. The liquid formulation of fluconazole can be adjusted according to renal function to ensure safe medication use.
Reducing drug accumulation: By adjusting the dosage, the accumulation of fluconazole in elderly patients can be reduced, lowering the risk of adverse reactions.
Clinical Advantages
High absorption rate
Fluconazole liquid boasts over 90% oral bioavailability, maintaining stable blood concentrations
Long half-life
Fluconazole has a 30-hour half-life; once-daily dosing sustains effective drug levels and boosts patient compliance.
Strong tissue penetration
Fluconazole can penetrate the blood-brain barrier, treating deep fungal infections.
Not affected by diet
The liquid formulation of fluconazole is not affected by diet, is convenient to take.
References
Sagatova AA, Keniya MV, Wilson RK, et al. Structural insights into binding of the antifungal drug fluconazole to Saccharomyces cerevisiae lanosterol 14α-demethylase[J].
Boonstra JM, Märtson AG, Sandaradura I, et al. Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of fluconazole in critically ill patients[J].
Chesdachai S, Rajasingham R, Nicol MR, et al. Minimum inhibitory concentration distribution of fluconazole against Cryptococcus species and the fluconazole exposure prediction model[J].
FAQ
Q1: What core mechanism does fluconazole rely on for antifungal effects?
A1: It inhibits fungal lanosterol 14α-demethylase to block cell membrane synthesis and suppress fungal proliferation.
Q2: What are the most common mild adverse reactions of fluconazole?
A2: Transient nausea, mild headache and slight abdominal discomfort, which usually ease after continuous administration.
Q3: Which infections are the primary clinical indications for oral fluconazole?
A3: Vulvovaginal candidiasis, oral thrush, esophageal candidiasis and mild cryptococcal infections.
Hot Tags: fluconazole liquid, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale